Company Profile

Jelikalite LLC (AKA: Jelikalite Corp)
Profile last edited on: 9/18/25      CAGE: 8CJX4      UEI: EM6KAHVY78N3

Business Identifier: Medical equipment manufacture
Year Founded
2019
First Award
2022
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

30 Wall Street Suite 811
New York, NY 10005
   (857) 636-0893
   N/A
   www.jelikalite.com
Location: Single
Congr. District: 10
County: New York

Public Profile

With Autism understood as a serious developmental disease lasting a lifetime, the rates of autism continue to rise, the cause of the disease remains unknown and there is no cure. We believe that children on the autism spectrum can lead fulfilling and productive lives. That is why JelikaLite is developing Cognilum, an integrative solution with focus on pediatric neurological health using non-invasive novel therapies. Cognilum will enable children to integrate into society, parents to receive a home-based personalized cost-effective treatment while having a better quality of life, therapists to track progress and efficacy of existing interventions, and both payors and government to spend less money on special education and lifelong residential care. Cognilum may provide benefits that may be difficult to measure with money alone, yet society will bear the ultimate expenses if nothing continues to be done about the millions of children with autism and other neurological disorders who are unable to integrate into society.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 1 NSF $256,000
Project Title: EEG-guided intelligent transcranial photobiomodulation to reduce symptoms of autism

Key People / Management

  Eugenia Steingold

  Katya Sverdlov

Company News

There are no news available.